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The penicillin allergy skin testing is the only accurate and reliable test for penicillin hypersensitivity 
mediated by IgE. It is useful for identifying patients with doubtful history of allergy. Positive test for 
major and minor determinants presents a positive predictive value of 50% and negative predictive value 
of 99%. In Brazil, the Ministry of Health suggests a protocol for in house made reagents, since they are 
not commercially available. As the referred protocol does not mention some important details about the 
test procedures, we propose in the present work to implement them, critically evaluating each step in 
order to allow the protocol establishment at any health service, with quality and safety.
Uniterms: Penicilin/allergy. Penicilin/cutaneous test. Skin test/penicilin allergy. Betalactamic/
hipersensitivity
O teste cutâneo para alergia imediata a penicilina é  o único teste validado internacionalmente, sendo que 
sua grande utilidade reside na avaliação de pacientes com história positiva de alergia a penicilina. O teste 
positivo para determinantes principais e secundários da penicilina apresenta um valor preditivo positivo 
de 50% e valor preditivo negativo de 99%. Em nosso meio, o Ministério de Saúde disponibiliza um 
protocolo para o preparo dos reagentes, uma vez que os mesmos não estão disponíveis comercialmente. 
Como o referido protocolo não apresenta maiores detalhes sobre o cuidado relativo às etapas de preparo 
das soluções, bem como faltam algumas considerações no que tange a realização do teste, propusemo-
nos no presente trabalho operacionalizar o teste, avaliando de forma crítica e minuciosa cada etapa, de 
forma que outros profissionais possam reproduzi-lo de maneira mais segura e eficaz.
Unitermos: Penicilina/alergia. Penicilina/teste cutâneo. Teste cutâneo/alergia penicilina. Betalactâmico/
hipersensibilidade.
INTRODUCTION
The beta-lactamic drugs, among them the peni-
cillins, are considered to be the first choice in a variety of 
pathologies, such as pneumococcal pneumonia, cerebral 
abscess, bacterial meningitis, syphilis, rheumatic fever, 
and post streptococcal glomerulonephritis (São Paulo, 
2003). However, the fear of a possible previous history 
of drug allergy commonly leads to the use of alternative 
antibiotics (Forrest, 2001). 
Although the percentage of patients with a suggesti-
ve history of penicillin allergy is about 0.7 to 10%, only 10 
to 30 % of them present positive cutaneous test (Forrest, 
2001). Many suggestive cases of drug allergy are, in fact, 
neurovegetative disturbances or vasovagal reactions, cha-
racterized by anxiety, fear, sweat, associated with pain or 
painful sensation related to the parenteral administration 
of drugs (Sarti, 2001). 
The clinical manifestations of drug allergy vary and 
depend on the type and severity, and on the affected organs; 
the skin is the most frequently affected organ. The preva-
lence of drug allergy among hospitalized patients is about 
0.36%, and the antibiotics are responsible for 55 % of the 
cutaneous manifestations (Gruchalla, Pirmohamed, 2003).
Drug allergy is induced by immunogenic deter-
minants from the drugs or their metabolites, generally 
conjugated to proteins (Nagao-Dias et al., 2004). For 
A. T. Nagao-Dias, A. C. Pereira, M. F. e Silva, E. D. R. Néri, J. W. Accioly, J. E. S. Lima568
instance, it is known that penicillin presents a major de-
terminant (benzylpenicilloyl group or BPO) and a minor 
determinants mix (MDM, constituted by benzylpenicillo-
ate, benzylpenicilloyl-amine, and benzylpenicilloic acid, 
among others). Unfortunately, the immunogenic compo-
nents from other drugs or their metabolites are in general 
not identified (Gruchalla, Pirmohamed, 2003), which 
becomes the laboratory investigation much more difficult.
The only internationally validated test for drug allergy 
diagnosis is the penicillin cutaneous test. The positivity of 
the test indicates the presence of IgE antibodies against the 
drug and, in this case, the patient has more risk for drug 
allergy upon re-exposition to the drug (Park, James, 2005). 
The positive predictive value of the test is considered to be 
50% and the negative predictive value is about 97 to 99% 
when the MDM and major determinants (penicilloyl-poly-
L-lysine or PPL-BPO) are included. The negative results in-
dicate that the patient can be re-exposed to the drug without 
great risk of immediate reaction after re-exposition (ACAII, 
1999; Wall et al., 2004; Park, James, 2005). In case of some 
reactions occurring after drug re-administration, in patients 
with positive history of drug allergy and negative cutaneous 
test, they are generally mild and limited; and anaphylaxis 
has never been observed in a person with negative cutaneous 
test results (Gruchalla, Pirmohamed, 2003).
Due to the impossibility to acquire the reagents 
for the cutaneous test, which are not commercially 
available in Brazil, a protocol has been proposed by the 
Brazilian Ministry of Health (Brasil,1999) for obtaining 
of the penicillin metabolites solution. Nevertheless, 
little is mentioned in the referred protocol about the 
implementation of the solution preparation process and 
the respective test procedure, which becomes difficult 
the test reproduction in a health service. For this reason, 
the present work proposes to evaluate the Ministry of 
Health protocol, according to the good manipulation 
practices and quality control.
MATERIALS AND METHODS
The solution preparation was carried out according 
to the Guide of penicillin cutaneous test from the Ministry 
of Health (Brasil, 1999).
Reagents preparation
Potassium G penicillin (PG)- 10,000 U/mL 
From a 1 million units of potassium G penicillin:
A 9.6 mL-solution of isotonic sodium chloride was 
added to a vial containing 1 million units of potassium G 
penicillin, obtaining a 100,000 U/ml-solution. The vial was 
identified as “100,000 U/mL- potassium G penicillin stock 
solution”, and kept for no more than 7 days under refrige-
ration (2 to 8 ºC). Before testing, a solution was prepared 
aseptically, diluting 1.0 mL of 100,000 U/mL- potassium 
G penicillin solution in 9.0 mL isotonic sodium chloride. 
The final solution contained 10,000 U/mL potassium G 
penicillin. This vial was identified as “daily solution of 
10,000 U/mL potassium G penicillin solution” and left 
for no more than 24 h under refrigeration (2 to 8 oC).
B-Stock solution of sodium benzylpenicilloate
In a sterile flask with 1 million units, 8.5 mL of 0.1 N 
sodium hydroxide and 1.5 mL isotonic sodium chloride 
were added aseptically. After mixing was complete, it 
was left for 45 min at room temperature, and then for 
48 h at 4 oC. The flask was identified as “stock solution 
of 0.125 M sodium benzylpenicilloate” with validity of 
30 days and kept under refrigeration (2 to 8o C).
Minor determinants mixture preparation (MDM) for 
daily use (benzylpenicillin/sodium benzylpenicilloate 
solution)
In a flask containing 8.2 mL of a sterile sodium 
chloride solution, we added 1.0 mL of the stock solution 
of 100,000 U/mL diluted penicillin and 0.8 mL of the sto-
ck solution of 0.125 M sodium benzylpenicilloate. After 
mixing, the flask was labeled as “MDM solution for daily 
use - 10,000 U/mL potassium G penicillin/ 1.0 x 10-2 M 
sodium benzylpenicilloate”, with validity of 24 h under 
refrigeration (2 to 8o C).
Cutaneous tests
Puncture test (prick test)
Asepsis of the palmar forearm skin surface was done 
with cotton embedded in 70% alcohol. After this, “MDM 
solution for daily use - 10,000 U/mL potassium G peni-
cillin/ 1.0 x 10-2 M sodium benzylpenicilloate” was aspi-
rated into a 1 mL-syringe and physiological saline (a control 
solution) into another syringe. One drop of the reagent and 
one drop of physiological saline were applied in distinct 
places with a minimal distance of 2 cm between them on the 
palmar forearm skin surface. The puncture was done with 
a disposable pricker, positioned at a 90o angle in relation to 
the skin, through a rotation movement. The results inter-
pretation was done after 15 to 20 min. The solutions excess 
was taken out with an absorbent paper exclusive for each 
solution. The test was considered negative when no altera-
tion was observed in the application site, in relation to skin 
color, pruritus or any other sign. The test was considered 
positive when a more intense response (papules, erythema 
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and/or pruritus) occurred, as compared to the physiological 
solution testing. In case of positive result, the patient would 
be considered allergic. In case of a negative result, the in-
tradermal testing should be performed.
Intradermal testing
In two separate syringes with 13 x 4 disposable 
needles, the daily solution of MDM (10,000 U/mL of po-
tassium G penicillin/1 x 10-2 M sodium benzylpenicilloate) 
and the physiological saline were aspirated. Following, 
0.01 to 0.02 mL of physiological saline (control solution) 
and the MDM solution were injected in distinct sites, 
with minimal distances of 2 cm between the drops on the 
palmar forearm, observing the formation of a papule with 
characteristic look of “orange peel”. After 15 to 20 min, 
the readings were done in the same way as the prick test.
A total of 20 individuals were tested, after signing a 
consent term. One of the participants was a patient atten-
ded at the hospital, with background history of penicillin 
allergy. He did not want to have the drug administered, al-
though penicillin was the drug of choice for his pathology. 
The other ones were professionals working at the Walter 
Cantídio University Hospital (WCUH) and students and 
professionals working at the Faculty of Pharmacy, FUC. 
A questionnaire was applied to the participants, containing 
information about previous use and/or occurrence of al-
lergic reactions after administration of penicillin or other 
beta-lactam drugs, preexisting diseases, current disease, 
use of medicines and other factors related to a background 
history of penicillin sensitivity.
The Project was approved by the Ethical Committee 
of the HUWC/UFC on February 24th 2004.
RESULTS AND DISCUSSION
The tests mostly used for evaluation of immediate 
hypersensitivity are the cutaneous tests, being extremely 
useful for evaluation of penicillin allergy. Except for the 
cutaneous tests, no other test is routinely used in clinics 
(Cerny et al., 2000; Primeau, Adkinson, 2001).
The test was done in 16 men and 4 women, in the 
age range between 18 and 54 years old, being the result 
negative for 19 of twenty participants. A patient attending 
at the hospital with a previous history of penicillin allergy 
showed negative results. An employee, for whom the test 
was positive, had a background history of allergy to po-
tassium diclofenac and trimethoprim-sulphamethoxazole. 
Biosafety aspects
One of the first aspects to take into account is related 
to the biosafety, of which there is no mention in the Guide 
of Penicillin Allergy test from the Brazilian Ministry of 
Health (1999). It is generally mentioned “aseptically” 
which could just mean a good disinfection of the bench. 
However, according to the Brazilian normative “Good 
practice of manipulation for human use in pharmacies” 
(RDC # 214, December 12th, 2006; ANVISA, Brasil), one 
must minimize possible risks of contamination during the 
solution preparation. For this reason, the RDC # 214, AN-
VISA (Brasil, 2006), recommends that the area destined to 
manipulation and bottling of sterile preparations be inde-
pendent and exclusive, provided with air filters for particle 
and microorganisms retention, keeping the recommended 
levels – Class ISO 5 (100 particles/ cubic feet of air) or 
under laminar flow Class ISO 5 (100 particles/ cubic feet 
of air), in area Class ISO 7 (10,000 particles/ cubic feet 
of air) from ISO 14644-1, and presenting positive pres-
sure in relation to the adjacent rooms, avoiding entry of 
contaminated external air. However, the same normative 
recommends that the manipulation of antibiotics must be 
done in an isolated place, inside a room provided with an 
antechamber. This place should present a negative pressure 
in relation to the adjacent rooms, being projected in order 
to avoid spreading of the powder into the laboratory and 
into the environment, in order to avoid cross contamina-
tion, and in this way protecting the manipulator and the 
environment. It is suggested that all the steps be done in a 
vertical laminar flow class II- A, with a frontal overture, 
air source, and exhaustion with HEPA filter for retention 
of particles and microorganisms, installed preferentially in 
an independent and exclusive room, including the last step 
of the preparation, that is, the final dilution of the MDM 
solution, before its application. The room surrounding the 
laminar flow must be Class ISO 7 (10,000 particles/ cubic 
feet of air), present a system of filters to avoid contami-
nation of the environment and must have an antechamber 
with a clothing room. In this way, the safety of the product, 
the environment and the manipulators will be maintained, 
complemented with the use of individual protection equip-
ment (IPE) when preparing the solutions and the adequate 
procedures of hygiene and cleaning, as washing hands 
with iodopovidone before and after manipulation.
MDM preparation
For the MDM preparation, the use of sodium hydro-
xide of high grade of purity (reagents of analytical purity – 
PA) is paramount. Otherwise the use of sodium hydroxide 
with lower grade of purity would imply the use of barium 
hydroxide for the precipitation of possible impurities, as 
indicated in the Brazilian Pharmacopeia (1926), through 
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the following method: initially, 100 mL of NaOH solution 
is prepared adding 0.4 g sodium hydroxide in recently 
boiled and cooled water and, following, a freshly prepa-
red saturated solution of barium hydroxide (2.5 g barium 
hydroxide in 50 mL hot distilled water) is added until no 
precipitation is formed. The mixture is shaken and left to 
rest till the following day in a closed flask. The solution 
is then filtered through a 0.22 mm filter (Millipore, USA). 
The solution is maintained in an sterilized plastic flask and 
kept during one year at maximum, and it must be tested 
for the presence of residual barium (Regulation number 
500, October 9th 1997, ANVISA, Brasil). It is necessary 
to check for the presence of residual barium because this 
can cause skin irritation (Brazil, 1997) and can give false 
positive results in the cutaneous tests
Test procedure
In respect to the cutaneous test with application of 
the MDM solution, it is suggested to use a dermographic 
pen, marking the sites of application with two traces on 
the palmar face of the forearm, being one for the test (T) 
and the other for the control (C), keeping a distance of 
2 cm between them as shown in figure 1. Following the 
solution application, a disposable pricker is positioned at 
a 90o angle on the palmar face of the forearm and rotated 
180 ºC in clockwise or anticlockwise sense.
Determinants of penicillin used by cutaneous tests 
The use of the major determinants, that is, BPO-
PPL, is not referred in the Guide of the Ministry of Health, 
but a solution containing diluted penicillin G or the MDM, 
this procedure differs from other papers, in which BPO-
PPL and MDM are used (Arroliga, Pien, 2003; Gruchalla, 
2003; Wall et al., 2004; Lammintausta, Kortekangas-
Savolainen, 2005). 
The only major determinants commercially available 
in the conjugated form of poly-L-lysine (BPO-PPL) was 
PRE-PEN, nonetheless, its production was interrupted in 
2005 (Park, Li, 2005). According to Sarti (1985), although 
PRE-PEN or BPO-PPL could detect 80% of the patients 
who are allergic to penicillin, the risk of immediate hyper-
sensitivity is resultant from reaction to minor determinants. 
According to the protocol suggested by the author 
(Sarti, 2001), which is the same from the Brazilian Ministry 
of Health (1999), the hydrolysate (MDM) contains benzyl-
penicilloate and other metabolites in lower quantities. Sarti 
(1985) considers the solution containing diluted penicillin 
G (PG) and minor determinants (MDM) to be effective 
in identifying patients with risk of larynx edema and ana-
phylactic shock, making unnecessary the use of BPO-PPL, 
as the last one just identifies accelerated reactions. Arroliga 
and Pien (2003) also consider that the greatest risk of severe 
reactions occurs against the minor determinants; nonethe-
less, they consider a high risk of anaphylaxis in patients 
whose tests were positive for any of the determinants, minor 
or major ones. Concerning the minor determinants, they are 
not commercially available, for this reason, different ways 
are proposed for their obtaining. Some authors propose to 
work with an aged solution of penicillin G, by leaving it at 4 
to 8º C for a period of 3 to 6 days before its dilution to 10,000 
U/mL in the tests (Lammintausta, Kortekangas-Savolainen, 
2005). However, other researchers are not in agreement with 
this kind of procedure (Arroliga, Pien, 2003). According to 
Wall et al. (2004), MDM can be obtained through penicillin 
dilution to a concentration of 10,000 U/mL just before the 
test application. According to Gruchalla and Pirmohamed 
(2001), with use of freshly diluted penicillin G in a concen-
tration of 10,000 U/mL as MDM, one can lose 5 to 10 % of 
positive tests, making it possible in these cases that a patient 
presents anaphylaxis upon re-administration of penicillin. 
In contraposition to the authors’ considerations, Sarti 
(1985) reports that 6,668 patients with negative results to 
MDM and diluted PG were treated without presenting any 
immediate allergic reaction, estimating a risk of systemic 
reaction of 1.5 per million of individuals with negative 
test upon re-administration of penicillin. This reinforces 
the hypothesis that the “in house” prepared method, as 
suggested by the author (Sarti, 1985), is reliable and safe 
for the evaluation of penicillin allergy.
Interpretation of the results
Concerning the interpretation of the results, accor-
ding to the protocol of the Brazilian Ministry of Health 
(1999), the result is considered negative when there is no 
alteration observed on the site of application, in respect 
FIGURE 1 - Application of the cutaneous test.
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to the skin color, to pruritus or any other kind of sign not 
referred by the patient. The result is considered positive, 
when there is a papule elevation (with or without erythe-
ma surrounding it), erythema and/or pruritus at the site of 
application, with a diameter at least 2 mm larger than the 
control. Other authors (Arroliga, Pien, 2003), differing 
from the protocol of the Brazilian Ministry of Health 
(1999), considered the results positive when the diameter 
of the test was at least 3 mm larger than the control, with 
erythema. Wall et al. (2004) include histamine as positive 
control. According to the authors, when both the penicillin 
and the histamine show reaction, the test is considered po-
sitive. In case the histamine shows a reaction, but not the 
penicillin, the test is considered negative. In this case, the 
risk of penicillin allergy is considered to be similar to the 
population in general. On the other hand, when the test is 
negative both for histamine and penicillin, it is interpreted 
as undetermined. The concentration of histamine is gene-
rally 1 mg/mL (Cetinkaya, Cag, 2004; Wall et al., 2004; 
Lammintausta, Kortekangas-Savolainen, 2005).
Consent term
In respect to the consent term, there is a diversity 
of opinions. According to Wall et al. (2004), when the 
patient is directed to an allergy test service, and he agrees 
with it, the pharmacist proceeds with the test, without 
the necessity of a formal consent, once the procedure has 
not an experimental character. According to Torres et al. 
(2003), in case the patient has a possible allergy reaction to 
a drug, the tests do not require an approval by a local ethics 
committee, just a written informed consent. The authors 
consider an approval by an ethics committee is necessary 
when the diagnostic methods are used in the context of 
clinical studies, for establishing the right dose for a cuta-
neous test, for instance, or a validation for a provocation 
test, and also, when the data are kept or distributes through 
a data bank.
CONCLUSIONS
The implementation of the penicillin cutaneous test 
was necessary for allowing the reproducibility and quality 
of the procedure. This way, we could elaborate standard 
operational procedures for the preparation of penicillin 
cutaneous test for hospital routine. Considering that the 
MDM-PG solution is for parenteral use, its preparation 
must be done in aseptic environment, by trained perso-
nal, in order to diminish the risk of contamination and to 
guarantee the solution sterility. 
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